Lauvsnes, Maria Boge http://orcid.org/0000-0002-4188-6640
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Kvaløy, Jan Terje http://orcid.org/0000-0002-8829-6250
Tjensvoll, Anne Bolette http://orcid.org/0000-0003-2495-5795
Maroni, Stian
Beyer, Mona K. http://orcid.org/0000-0001-9156-6357
Greve, Ole Jacob http://orcid.org/0000-0003-1147-2292
Kvivik, Ingeborg http://orcid.org/0000-0002-6678-9302
Alves, Guido http://orcid.org/0000-0003-0630-2870
Gøransson, Lasse Gunnar
Harboe, Erna
Hirohata, Shunsei
Omdal, Roald http://orcid.org/0000-0002-6051-4658
Funding for this research was provided by:
Helse Vest (F-12525, 912129, 911807)
Vetenskapsrådet (2018-02532, 2017-00915)
H2020 European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
The Swedish Alzheimer's Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Norges Forskningsråd (287842)
The Norwegian Parkinson Research Foundation
Reberg's Legacy
Japan Agency for Medical Research and Development (15eK0410022h0001)
Article History
Received: 9 September 2021
Revised: 4 November 2021
Accepted: 5 November 2021
First Online: 20 November 2021
Change Date: 23 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-024-12238-y
Declarations
:
: Dr. Henrik Zetterberg reports that he served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Kaj Blennow has served as a consultant or on advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Mona Beyer has received Honoria for lecturing from Novartis and Biogen Idec, Merck AB, Roche Norge, and Sanofi Genzyme. Drs. Lasse G. Gøransson and Roald Omdal has received speaker honoraria from several pharmaceutical companies. None of the other authors have any conflict of interest with regard to the work.
: This study complied with the Helsinki Declaration and was approved by the Regional Research Ethics Committee (REKvest 2010/1455).
: Written informed consent was obtained from all patients.